Searched for
DR REDDY NEWS
Hyderabad Economic Forum 2026 brings together 500+ leaders at SAS ITOWER to chart the city’s next growth chapterHyderabad's economic future took center stage at the inaugural Hyderabad Economic Forum 2026, themed 'One City. One Vision. Infinite Possib...- Stocks in news: Dr Reddy’s, Adani Green, KIMS, JSW Energy, Nestle IndiaMarkets saw a strong rebound on Friday, driven by positive global cues and easing geopolitical tensions. Nifty defended the 23,000 support ...
- Stocks in news: ITC, Nykaa, Lenskart, Ola Electric, IndusInd BankMarkets saw a volatile session with Nifty trading below the 23,800-24,000 resistance zone, though select heavyweight buying limited downsid...
- Reddy Pharma loses 'name' in Delhi HC rulingThe Delhi High Court has ruled against Reddy Pharmaceuticals. The court upheld a decision to remove 'Reddy' from the company's name. Reddy ...
- Stocks in news: Vodafone Idea, Indian Oil, Tata Steel, Dr Reddy's, PFCMarkets closed lower amid geopolitical tensions, rupee weakness, and rising inflation. Upcoming week will be sensitive to US-Iran conflict ...
- Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...
- Stocks in news: Airtel, Tata Motors, Dr Reddy's, NTPC, Dixon TechnologiesMarkets faced selling pressure on Tuesday due to weak global cues and macroeconomic concerns, with the Nifty approaching support at 23,150....
- Stocks in news: Groww, Dr Reddy's, Waaree Energies, Lenskart, SBIMarkets experienced a sharp risk-off session on Monday, with indices declining amid broad selling. Investors are advised to avoid aggressiv...
- Q4 earnings, crude oil, FII action among 8 factors to steer D-Street this weekIndian stock markets are set for a busy week. Key events like Q4 earnings announcements for many companies will influence trading. Foreign ...
- KPIT Technologies among 5 F&O stocks with a sharp rise in futures open interestFive NSE F&O stocks, including KPIT Technologies and Blue Star, saw a sharp rise in futures open interest as of May 7, indicating fresh pos...
- Ahead of Market: 10 things that will decide stock market action on TuesdayIndian markets ended higher driven by positive election trends, with gains in financials, pharma, and metals. Nifty held above key support ...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Dr Reddy’s shares fall 2% after Goldman Sachs downgrades, Citi turns cautiousDr Reddy’s shares fell after Goldman Sachs and Citigroup turned cautious, citing limited growth visibility, pipeline concerns and valuation...
- Dr. Reddy’s Laboratories shares in focus on denial of workforce reductionDr. Reddy’s Laboratories shares: In a regulatory filing, the pharmaceutical giant addressed a Business Standard article dated April 13, whi...
- Buy Dr. Reddy's Laboratories, target price Rs 8010: JM FinancialDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 116021.72 Crore) operating ...
- Buy Dr. Reddy's Laboratories, target price Rs 6500: Prabhudas LilladherDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 106802.89 Crore) operating ...
- Buy Dr. Reddy's Laboratories, target price Rs 6500: Prabhudas LilladherDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 96680.36 Crore) operating i...
- Buy Dr. Reddy's Laboratories, target price Rs 6935: JM FinancialDr. Reddy's Laboratories Ltd. key Products/Revenue Segments include Pharmaceuticals, Licence Fees, Other Operating Revenue, Spent Chemicals...
- Dr Reddy's shares rise 4% on Q3 PAT jump but brokerages remain unmoved. Here's whyThe drug maker on Tuesday reported an 11% year-on-year (YoY) jump in net profit at Rs 1,379 crore for the quarter ended December 31, 2023, ...
- Licence to sell cancer drug biggest opportunity for Dr Reddy’s in US market: Nirmal Bang‘On a very conservative basis, the drug can add about $300 million to their sales in FY23-FY24.’
Load More
